Help us: Donate
Follow us on:



Developing metabolic therapies for sarcopenia

Biophytis is developing Sarconeos, a compound that activates the MAS receptor in order to target three critical downstream metabolic pathways: mTOR, AMPK, and MAPK. This compound is currently in Phase 2 clinical trials as a therapy for sarcopenia, the age-related loss of muscle mass that leads to frailty and weakness, and it is using functional abilities, such as walking speed, as its endpoints.

Biophytis also has therapies for Duchenne muscular dystrophy and age-related macular degeneration in preclinical phases.

While this is a French company, it maintains a website in English.